Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study
| dc.contributor.author | Barrios, C. H. | |
| dc.contributor.author | Herbst, R. S. | |
| dc.contributor.author | de Marinis, F. | |
| dc.contributor.author | Giaccone, G. | |
| dc.contributor.author | Reinmuth, N. | |
| dc.contributor.author | Vergnenegre, A. | |
| dc.contributor.author | Morise, M. | |
| dc.contributor.author | Felip, E. | |
| dc.contributor.author | Andric, Z. | |
| dc.contributor.author | Geater, S. | |
| dc.contributor.author | Ozguroglu, M. | |
| dc.contributor.author | Mocci, S. | |
| dc.contributor.author | McCleland, M. | |
| dc.contributor.author | Zou, W. | |
| dc.contributor.author | Enquist, I. | |
| dc.contributor.author | Komatsubara, K. | |
| dc.contributor.author | Deng, Y. | |
| dc.contributor.author | Kuriki, H. | |
| dc.contributor.author | Spigel, D. R. | |
| dc.contributor.author | Jassem, J. | |
| dc.date.accessioned | 2021-03-06T10:58:27Z | |
| dc.date.available | 2021-03-06T10:58:27Z | |
| dc.identifier.citation | Herbst R. S. , de Marinis F., Giaccone G., Reinmuth N., Vergnenegre A., Barrios C. H. , Morise M., Felip E., Andric Z., Geater S., et al., "Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study", Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva, İsviçre, 11 - 14 Aralık 2019, cilt.30, ss.62-63 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_ecf1f604-7b9b-42b3-b8b3-b0f3eb4ac257 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/155536 | |
| dc.language.iso | eng | |
| dc.subject | İç Hastalıkları | |
| dc.subject | ONKOLOJİ | |
| dc.subject | Klinik Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Tıp | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | Onkoloji | |
| dc.title | Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study | |
| dc.type | Bildiri | |
| dc.contributor.department | Yale University , , | |
| dc.identifier.volume | 30 | |
| dc.contributor.firstauthorID | 157791 |
Bu öğenin dosyaları:
| Dosyalar | Boyut | Biçim | Göster |
|---|---|---|---|
|
Bu öğe ile ilişkili dosya yok. |
|||
Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.
-
Bildiri [64839]